Greywolf Therapeutics

Grey Wolf Therapeutics is a clinical-stage biotechnology company developing small molecule inhibitors of endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) to modulate antigen presentation on cell surfaces.

In oncology, this approach enhances tumour visibility to the immune system; in autoimmunity, it aims to correct aberrant immune recognition.

The company's lead candidate, GRWD5769, is in Phase 1/2 trials for solid tumours, with a second programme targeting autoimmune indications advancing through preclinical development.